<VariationArchive RecordType="classified" VariationID="2425614" VariationName="NC_000006.11:g.(?_5216831)_(5431425_?)del" VariationType="Deletion" Accession="VCV002425614" Version="3" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-11" DateCreated="2023-02-13" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1939621" VariationID="2425614">
      <GeneList>
        <Gene Symbol="FARS2" FullName="phenylalanyl-tRNA synthetase 2, mitochondrial" GeneID="10667" HGNC_ID="HGNC:21062" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>6p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5249934" stop="5771583" display_start="5249934" display_stop="5771583" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="5261583" stop="5771815" display_start="5261583" display_stop="5771815" Strand="+" />
          </Location>
          <OMIM>611592</OMIM>
        </Gene>
        <Gene Symbol="LYRM4" FullName="LYR motif containing 4" GeneID="57128" HGNC_ID="HGNC:21365" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>6p25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="5031753" stop="5260950" display_start="5031753" display_stop="5260950" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="5108652" stop="5261171" display_start="5108652" display_stop="5261171" Strand="-" />
          </Location>
          <OMIM>613311</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000006.11:g.(?_5216831)_(5431425_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" innerStart="5216831" innerStop="5431425" display_start="5216831" display_stop="5431425" variantLength="214595" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.(?_5216831)_(5431425_?)del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.(?_5216831)_(5431425_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000006.11:g.(?_5216831)_(5431425_?)del AND Combined oxidative phosphorylation defect type 14" Accession="RCV003109538" Version="3">
        <ClassifiedConditionList TraitSetID="9027">
          <ClassifiedCondition DB="MedGen" ID="C4755312">Combined oxidative phosphorylation defect type 14</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-10-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-10-20" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2023-11-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22833457</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9027" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17497" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Combined oxidative phosphorylation defect type 14</ElementValue>
                <XRef ID="MONDO:0013986" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Combined oxidative phosphorylation deficiency 14</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">COXPD14</ElementValue>
                <XRef Type="MIM" ID="614946" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17455" />
                <XRef ID="17455" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families. Infantile-onset phenotype. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of affected children die in early childhood. Later-onset phenotype. All affected individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.</Attribute>
                <XRef ID="NBK538658" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">30869852</ID>
                <ID Source="BookShelf">NBK538658</ID>
              </Citation>
              <XRef ID="319519" DB="Orphanet" />
              <XRef ID="C4755312" DB="MedGen" />
              <XRef ID="MONDO:0013986" DB="MONDO" />
              <XRef Type="MIM" ID="614946" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7074514" SubmissionDate="2023-02-03" DateLastUpdated="2023-11-11" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_006567.3_Deletion (Exons 1-4)|MedGen:C3554168" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003791518" DateUpdated="2023-11-11" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22833457</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 1-4 of the FARS2 gene, which includes the initiator codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FARS2 are known to be pathogenic (PMID: 22833457). This variant has not been reported in the literature in individuals affected with FARS2-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FARS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.(?_5216831)_(5431425_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3554168" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7074514" TraitType="Disease" MappingType="XRef" MappingValue="C3554168" MappingRef="MedGen">
        <MedGen CUI="C4755312" Name="Combined oxidative phosphorylation defect type 14" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

